Table 3

Combined Caucasian cohorts were partitioned into two arbitrarily defined disease categories: (i) seroconverter patients who progress to AIDS outcome in ≤6 years after HIV-1 infection and (ii) seroconverter patients who avoid AIDS outcome for ≥10 years. Relative risk (RR) and attributable fraction (AF) were computed on the basis of established methods (29, 30). Freq. susc. genotype, frequency of susceptible genotype.

Risk factor and AIDS outcomeNFreq. susc. genotypeRapid progression to AIDS*Long-term survival*
RR PAF (%) RR PAF (%)
HLA class I homozygosity
AIDS-1993 320 26.3% 1.460.007 10.82.230.005 47.6
AIDS-1987 31626.3% 1.37 0.15 8.9 1.61 0.02 30.8
Death 313 26.3% 1.33 0.40 8.0 1.410.03 23.2
B*35, Cw*04homo/ heterozygotes
AIDS-1993 320 24.0% 1.310.07 6.8 1.82 0.02 38.3
AIDS-1987 31624.0% 2.18 8 x 105 22.0 1.700.009 34.7
Death 313 24.0% 2.45 0.00425.8 1.80 0.0002 37.9
HLA-homozygotes or B*35,Cw*04 genotypes
AIDS-1993 32046.7% 1.52 0.0008 19.4 2.276 × 10−5 40.4
AIDS-1987 31646.7% 2.02 0.0002 32.3 1.78 0.0002 29.3
Death 313 46.7% 1.93 0.03 30.2 1.738 × 10−6 27.9
  • * For rapid progressors, the risk factors include homozygosity at one or more class I loci, the presence of at least one B*35or Cw*04 allele, or both. For slow- and long-term survivors, alternative protective factors (full heterozygosity, absence ofB*35 or Cw*04 allele, or both) were considered in computing values.